REPLIGEN CORP acquires Tantti Laboratory Inc.

REPLIGEN CORP acquired Tantti Laboratory Inc. for ~$54.8 million cash (net of cash acquired), plus up to $54.5 million earnout, a transaction completed in December 2024, structured as cash (share swap / share purchase) with contingent earnout.

Tantti Laboratory Inc. operates in Proteins / Chromatography, is based in Taoyuan City, Taiwan, had revenue of about an undisclosed amount (no associated revenue in FY2024). Acquisition of Tantti Laboratory Inc. of Taoyuan City, Taiwan, developer of a portfolio of macroporous chromatography beads (including Dulocore base bead technology) to optimize purification of new modalities such as viral vectors, viruses and nucleic acids. The technology underpins Repligen's HiPer base beads and AVIPure resin extensions. Tantti contributed $78.1 million of total assets and no revenue as of Dec 31, 2024.

Per Repligen's 10-K, the Tantti acquisition is expected to accelerate expansion into new-modality markets with unique, scalable purification solutions for larger-molecule biologics.

Base-bead technology enabling new-modality purification resins (HiPer, AVIPure). Combines with Avitide affinity ligands to extend the Proteins resin portfolio. Repligen Proteins / Chromatography (Repligen Sweden AB subsidiary)

With our acquisition of Tantti Laboratory Inc. on December 2, 2024, we expect to accelerate our expansion into new modality markets with unique, scalable purification solutions for these larger molecule biologics.Repligen FY24 10-K, Item 1 Business / 2024 Acquisition note

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.